Viking Therapeutics Inc.’s stock fell 5.6% Friday, in a pullback from recent highs, after strong data from Novo Nordisk on an oral version of its weight-loss drug raised the competitive bar for Viking, which is expected to release data from its oral-drug trial late this quarter.


Source link

Leave a Reply

Your email address will not be published. Required fields are marked *